RxDoctor Payments Data

Debra Ahrensfield, MD

Internal Medicine · Schuylkill Haven, PANPI 1699763813

Payments from drug & device makers

$245in general payments, 2019–2025

Across 16 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$77
  • AbbVie$70
  • AstraZeneca$40
  • Amarin Pharma, Inc.$28
  • GSK$16
  • Amgen$14

What the payments were for

  • Food & beverage$245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$77
AbbVie3$70
AstraZeneca3$40
Amarin Pharma, Inc.2$28
GSK1$16
Amgen1$14

How this compares

$245 in reported general payments places this provider in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$83,457
Medicare patients
273
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$75,178
JanuviaSitagliptin Phosphate42$41,610
TrulicityDulaglutide24$33,841
JardianceEmpagliflozin33$33,178
OzempicSemaglutide12$25,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,640
LinzessLinaclotide13$12,206
SymbicortBudesonide/Formoterol Fumarate16$6,490
FarxigaDapagliflozin Propanediol11$6,232
Atorvastatin Calcium333$2,902
Levothyroxine Sodium303$2,648
Albuterol Sulfate HfaAlbuterol Sulfate90$2,550
Metoprolol Succinate154$2,088
Potassium Chloride56$1,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$25,94912 claims
GSKTrelegy Ellipta$16$15,64012 claims
AbbVieLinzess, Synthroid, Armour Thyroid$70$14,07950 claims
AstraZenecaSymbicort, Farxiga$40$12,72327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Schuylkill Haven

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →